Carbapenemases produced by Carbapenem-resistant Pseudomonas aeruginosa isolated from hospitals in Chile
Published 2021-03-20
How to Cite
Copyright (c) 2021 Jandira Tomás Da Costa, Celia A Lima, Alejandra Vera-Leiva, Ivan San Martín Magdalena, Helia Bello-Toledo, Mariana Dominguez Yevenes, Andrés Opazo-Capurro, Sergio Mella Montecinos, Mario Quezada-Aguiluz, Gerardo González-Rocha

This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Background: Carbapenem resistance mediated by carbapenemases in Pseudomonas aeruginosa is an important mechanism; however, loss of porin OprD remains as the most frequent. Aim: To determine the proportion of P. aeruginosa isolates, resistant to imipenem and/or meropenem, producing carbapenemases, the type of enzyme produced and the genetic relationship between the isolates. Methods: One hundred andthirteen resistant to at least one carbapenem isolates, obtained in 12 hospitals and 9 cities in Chile were studied. Additionally, susceptibility to ceftazidime, amikacin, gentamicin, piperacillin/tazobactam, ciprofloxacin and colistin was determined. Carba NP was performed and in the positive isolates carbapenemase genes were detected by PCR. The isolates were typified by restriction with SpeI and PFGE. Results: Not all isolates produce carbapenemases, and only in 61/113 of them (54%) the blaKPC (32) or blaVIM (29) was amplified. In none of the isolates was found the coharboring of both genes. The pulsotypes indicated no clonal dissemination of the isolates, evidencing an important genetic diversity. Conclusions: P. aeruginosa isolates producing carbapenemases, obtained in Chilean hospitals carry blaKPC and blaVIM genes and, mostly, are polyclonal. These results emphasize the importance of carrying out epidemiological studies with a greater number of isolates to allow a better understanding of the epidemiology of carbapenemase-producing P. aeruginosa in Chile.
